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Abstract
Objective Our aim was to assess the safety of cyclooxygenase-2 (COX-2) inhibitors in the management of osteoarthritis 
(OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials.
Methods A comprehensive literature search was undertaken in the databases MEDLINE, Cochrane Central Register of 
Controlled Trials (Ovid CENTRAL) and Scopus. Randomized, double-blind, placebo-controlled, parallel-group trials that 
assessed adverse events (AEs) with COX-2 inhibitors in patients with OA were eligible for inclusion. Two authors appraised 
titles, abstracts and full-text papers for suitability and then assessed the studies for random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective 
outcomes reporting. The primary outcomes of interest were gastrointestinal disorders, cardiac disorders, vascular disorders, 
nervous system disorders, skin and subcutaneous tissue disorders, hepatobiliary disorders, renal and urinary disorders, as 
well as overall severe and serious AEs, drug-related AEs and mortality. Secondary outcomes were withdrawals due to AEs 
(i.e. the number of participants who stopped the treatment due to an AE) and total number of AEs (i.e. the number of patients 
who experienced any AE at least once).
Results Database searches identified 2149 records from which, after exclusions, 40 trials were included in the meta-analysis. 
The use of COX-2 inhibitors in OA was associated with a significant increased risk of drug-related AEs compared with 
placebo (relative risk (RR) 1.26, 95% CI 1.09–1.46; I2 = 24%). The risk of upper gastrointestinal complications (includ-
ing dyspepsia, gastritis and heartburn) was significantly increased with COX-2 inhibitors versus placebo (RR 1.19, 95% 
CI 1.03–1.38; I2 = 0%), particularly for abdominal pain, which increased by 40% with COX-2 inhibitors (RR 1.40, 95% CI 
1.08–1.80; I2 = 0%). The risk of hypertension increased by 45% overall (RR 1.45, 95% CI 1.01–2.10; I2 = 25%); however, 
when rofecoxib was removed from the analysis the risk of hypertension in the COX-2 inhibitor group was no longer signifi-
cant (RR 1.21, 95% CI 0.80–1.83; I2 = 20%). The overall risk of heart failure and edema was increased by nearly 70% with 
COX-2 inhibitors versus placebo (RR 1.68, 95% CI 1.22–2.31; 0%) and this level of risk did not change appreciably when 
rofecoxib was excluded (RR 1.67, 95% CI 1.21–2.29; 0%).
Conclusions In our analysis, COX-2 inhibitors were associated with an increased risk of upper gastrointestinal AEs, espe-
cially abdominal pain. We also found an increased risk of cardiovascular AEs with COX-2 inhibitors, namely hypertension, 
heart failure and edema.
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1 Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the 
enzyme cyclooxygenase (COX), which mediates the con-
version of arachidonic acid to inflammatory prostaglandins 
(PGs). COX-1 is constitutively expressed in the gastric epi-
thelium, therefore providing protection to the gastric mucosa 
as it regulates the production of acid and mucus. COX-2 is 
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Key Points 
Although specifically designed to avoid the gastrointes-
tinal side effects associated with non-selective NSAIDs, 
our analysis shows that cyclooxygenase-2 (COX-2) 
inhibitors are associated with an increased risk of upper 
gastrointestinal adverse events (AEs), especially abdomi-
nal pain, when used to treat pain in osteoarthritis (OA).
As expected, COX-2 inhibitors were associated with 
an increased risk of cardiovascular AEs; the risk of 
heart failure and edema remained significant even when 
rofecoxib was removed from the analysis.
These results confirm that a cautious approach to the 
use of COX-2 inhibitors (as for other NSAIDs) for the 
symptomatic management of pain and inflammation in 
OA is advisable, limiting use to intermittent or cyclical 
use rather than chronic treatment in order to minimize 
safety concerns.
COX-2 inhibition leads to reduced  PGI2 from the vascu-
lar endothelium; thus, the protective effect of  PGI2 is lost, 
which predisposes to injury, cell adhesion and vessel con-
traction.  TXA2 production by platelets is not inhibited by 
COX-2 inhibitors, which leads to platelet activation and a 
prothrombotic state (Fig. 1) [7].
There are meta-analyses comparing the relative safety of 
COX-2 inhibitors with non-selective NSAIDs [8–14]. How-
ever, the objective of this study was to assess the safety of 
oral COX-2 inhibitors in the management of OA in a sys-
tematic review and meta-analysis of randomized, placebo-
controlled trials.
2  Methods
The protocol of this systematic review and meta-analysis 
was previously registered in the PROSPERO database 
(registration number: CRD42017068278). The systematic 
review was performed in accordance with the recommenda-
tions in the Cochrane Handbook for Systematic Reviews of 
Interventions [15]. The findings were reported according to 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [16]. All the review 
process (study selection and risk of bias assessment) was 
undertaken using Covidence, the Cochrane platform for sys-
tematic reviews, and was performed by EC, NF, SS and LS.
2.1  Eligibility Criteria
Randomized, double-blind, placebo-controlled, paral-
lel-group trials that have assessed the AEs associated 
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Fig. 1  Effect of cyclooxygenase (COX) inhibition on platelets and 
endothelium. NSAID non-steroidal anti-inflammatory drug
involved in inflammation and is a source of the inflammatory 
mediators prostaglandin  E2  (PGE2) and prostacyclin  (PGI2) 
via the arachidonic acid pathway [1]. COX-2 inhibitors are 
a subclass of NSAIDs that were designed to selectively 
interrupt the production of inflammatory mediators without 
compromising gastric epithelial function [2]. COX-2 inhib-
itors are indicated for anti-inflammatory, anti-pyretic and 
analgesic effects in disorders such as osteoarthritis (OA), 
rheumatoid arthritis (RA) and acute pain.
There are few COX-2 inhibitors in current clinical use: 
celecoxib (200 mg/day, oral), etoricoxib [60 mg/day, oral; 
although not approved by the US Food and Drug Admin-
istration (FDA)] and parecoxib (80 mg/day, intravenous or 
intramuscular injection for postoperative pain; not approved 
by the FDA). Further, the FDA and European Medicines 
Agency (EMA) have withdrawn approval for other COX-2 
inhibitors due to an increased risk of cardiovascular adverse 
events (AEs); rofecoxib was withdrawn in 2004 due to 
thrombotic cardiovascular events observed in a randomized 
controlled trial (RCT) [3]; valdecoxib was withdrawn in 
2005 due to skin reactions and cardiovascular events post-
coronary artery bypass graft surgery in two RCTs [4, 5]; 
and lumiracoxib was withdrawn by the EMA in 2007 due 
to liver toxicity and skin reactions [6], and did not gain full 
FDA approval.
The proposed mechanism for an increase in occurrence of 
cardiovascular events is an imbalance between prostacyclin 
and thromboxane  A2  (TXA2), with prostacyclin production 
decreased but  TXA2 continuing, leading to platelet activa-
tion, vascular proliferation, vascular contraction and cell 
adhesion, which may occur within the coronary arteries. 
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valdecoxib but not lumiracoxib as it never gained full FDA 
approval) in patients with OA were eligible for inclusion in 
this meta-analysis.
Studies that allowed concomitant anti-osteoarthritis 
treatments during the trial (other than rescue medication 
as acetaminophen or aspirin) were also excluded, as were 
animal trials.
2.2  Data Sources and Search Strategies
A comprehensive literature search was undertaken in the fol-
lowing databases: MEDLINE (via Ovid), Cochrane Central 
Register of Controlled Trials (Ovid CENTRAL) and Sco-
pus. Each database was searched from inception up to 30 
June 2017. We searched for randomized placebo-controlled 
trials of COX-2 inhibitors in OA, using a combination of 
study design-, treatment- and disease-specific key words and 
Medical Subject Heading (MeSH) terms.
While adverse effects were the outcomes of interest for 
this study, we decided to avoid the outcome-specific key 
words in the search strategies, because of the possibility that 
a study on the efficacy of a drug may have not mentioned 
terms related to adverse events in its title, abstract or in the 
keyword section. The search was limited to English and 
French publications and to human subjects. Detailed search 
strategies for MEDLINE/CENTRAL and Scopus databases 
are reported as Electronic Supplementary Material (ESM1).
Two clinical trial registries, ClinicalTrials.gov (clinical-
trials.gov/) and the World Health Organization’s Interna-
tional Clinical Trials Registry Platform Search portal (apps.
who.int/trialsearch/) were also checked for trial results that 
were unpublished. Finally, recent meta-analyses were also 
screened for any additional relevant studies.
2.3  Study Selection
Two members of the review team independently evaluated 
each title and abstract to exclude only obvious irrelevant 
studies, according to the predefined eligibility criteria. At 
this step, the criteria related to adverse effects was not con-
sidered for selection, as studies focusing on the efficacy of 
a treatment may not report data about adverse effects in the 
abstract; this means that all trials mentioning only the effi-
cacy information were retrieved at this step. After this first 
step, the two investigators independently reviewed the full 
text of each of the articles not excluded during the initial 
screening stage to determine whether the studies met all 
selection criteria. At this stage, studies were excluded due 
to previously unidentified duplication, conference abstracts 
alone being available, a non-placebo comparator being used 
alone against COX-2 medication in the trial, an indication 
other than OA, safety not being included as an outcome 
of the trial, a non-COX-2 intervention or incorrect study 
design. All differences of opinion regarding the selection 
of articles were resolved through discussion and consensus 
between the two investigators; any persistent disagreement 
was solved with the intervention of a third person (another 
member of the review team).
2.4  Data Extraction
The full texts of the selected studies were screened by inde-
pendent reviewers for extraction of relevant data, using a 
standard data extraction form. Outcome results data were 
independently extracted by two investigators from the review 
team. For each study, the following data were extracted: 
characteristics of the manuscript, characteristics of the 
trial, objective and design of the study, characteristics of 
the patients, characteristics of the disease, characteristics 
of the treatments, AEs (outcomes) reported during the trial 
and the main conclusion of the study. In the case of multiple 
dosage arms for COX-2 inhibitors being included in a trial, 
the maximum dose was used to categorize the study. If mul-
tiple follow-up times were included, the longest follow-up 
time was used to categorize the study. The raw data (number 
of events in each group) were extracted for each outcome. 
The number of patients who experienced at least once any 
body-system–related AE (e.g. nervous system, gastrointes-
tinal system), as well as AEs within each body system (e.g. 
headache, abdominal pain) were extracted. As much as pos-
sible, data from the intention-to-treat (ITT) analysis were 
considered.
2.5  Outcomes of Interest
The main System Organ Classes (SOCs) that are likely to be 
affected by the use of COX-2 inhibitors in the treatment of 
OA were explored in this meta-analysis. The primary out-
comes of interest were gastrointestinal disorders, cardiac dis-
orders, vascular disorders, nervous system disorders, skin 
and subcutaneous tissue disorders, hepatobiliary disorders, 
renal and urinary disorders, as well as overall severe and 
serious AEs, drug-related AEs and mortality. Secondary out-
comes were withdrawals because of AEs (i.e. the number of 
participants who stopped the treatment because of an AE) 
and total number of AEs (i.e. the number of patients who 
experienced any AE at least once).
2.6  Assessment of Risk of Bias in Included Studies
Two authors of the review team independently assessed the 
risk of bias in each study using the Cochrane Collaboration’s 
tool for risk of bias assessment [15]. The following charac-
teristics were evaluated:
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• Random sequence generation: we assessed whether the 
allocation sequence was adequately generated.
• Allocation concealment: we assessed the method used 
to conceal the allocation sequence, evaluating whether 
the intervention allocation could have been foreseen in 
advance.
• Blinding of participants and personnel: we assessed the 
method used to blind study participants and personnel 
from knowledge of which intervention a participant 
received and whether the intended blinding was effective.
• Blinding of outcome assessment: we assessed the method 
used to blind outcome assessors from knowledge of 
which intervention a participant received and whether 
the intended blinding was effective.
• Incomplete outcome data: we assessed whether partici-
pants’ exclusions, attrition and incomplete outcome data 
were adequately addressed in the paper.
• Selective outcomes reporting: we checked whether there 
was evidence of selective reporting of adverse events.
Each of these items was either categorized as ‘low risk of 
bias’, ‘high risk of bias’, or ‘unclear risk of bias’. ‘Low risk 
of bias’ or ‘high risk of bias’ was attributed to an item when 
there was sufficient information in the manuscript to judge 
the risk of bias as ‘low’ or ‘high’; otherwise, ‘unclear risk of 
bias’ was attributed to the item. Disagreements were solved 
by discussion between the two reviewers during a consensus 
meeting and involved, when necessary, another member of 
the review team for the final decision.
2.7  Data Analysis
Analyses were performed using STATA 14.2 software. The 
units of analysis were the number of participants experienc-
ing a specific adverse event. We described harms associ-
ated with the treatment as risk ratio with 95% confidence 
interval (95% CI). We computed an overall effect size for 
each primary or secondary outcome (AE). Anticipating sub-
stantial variability among trial results (i.e. the inter-study 
variability), we assumed heterogeneity in the occurrence of 
the AEs; thus, we planned to use random-effects models for 
the meta-analyses. We estimated the overall effects and het-
erogeneity using the DerSimonian and Laird random-effects 
model [17]. As this method provides a biased estimate of 
the between-study variance with sparse events [18, 19], we 
also performed the meta-analyses using the Restricted Maxi-
mum Likelihood (REML) method [20]. As rofecoxib was 
withdrawn by the FDA and EMA in 2004 due to thrombotic 
cardiovascular events, we performed a sensitivity analysis 
for AEs for the COX-2 inhibitor class minus rofecoxib.
We tested heterogeneity using the Cochran’s Q test. As 
we are performing a random-effect meta-analysis, we used 
the Tau-squared (τ2) estimate as the measure of the between-
study variance. The I-squared (I2) statistic was used to quan-
tify heterogeneity, measuring the percentage of total varia-
tion across studies due to heterogeneity [21]. The quality 
of each evidence was assessed using the GRADE approach 
[22] and a summary of findings table was prepared using 
GRADEpro online software [23].
3  Results
3.1  Study Selection
Database searches initially identified 2149 records. After 
exclusions, 73 articles were screened in full against the 
inclusion criteria. A flowchart (Fig. 2) with the number 
of included studies at each step was established, including 
the reasons for excluding studies during the full-text read-
ing process. Forty-one of these met the eligibility criteria 
and included a placebo comparator, but a further five were 
excluded as the specific outcomes of interest to our strategy 
were not specified. Thirty-six papers were included, which 
actually comprised 40 trials as four papers presented results 
from two studies [24–58].
3.2  Study Characteristics
Table 1 presents the characteristics of the studies included 
through the systematic review process. The year of publi-
cation of the included studies ranged from 1999 to 2017 
and the follow-up time ranged from 6 weeks to 24 months. 
The number of trials including an arm for each specific 
COX-2 inhibitor (or two arms if two COX-2 inhibitors were 
included) were as follows: celecoxib 20 (49%), etoricoxib 
6 (15%), rofecoxib 10 (24%), celecoxib and etoricoxib 
4 (10%), celecoxib and rofecoxib 1 (2%). The anatomic 
regions included per trial are as follows; knee 24 (59%), hip 
2 (5%), knee or hip 13 (32%), any OA 1 (2%), not specified 
1 (2%).
3.3  Risk of Bias of Individual Studies
Figures 3 and 4 include a summary of the risk of bias 
assessed for each study included in the meta-analysis and 
all our findings were associated with a ‘moderate’ to ‘high’ 
certainty of evidence.
3.4  Primary Outcomes
We reported only the results from the DerSimonian and 
Laird random-effects model, because we found no differ-
ence in the effects computed by the two methods.
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3.4.1  Gastrointestinal Complications
The relative risk of upper gastrointestinal complications 
overall, including ulcer-related events, dyspepsia and 
abdominal pain, was significantly increased with COX-2 
inhibitors versus placebo (RR 1.19, 95% CI 1.03–1.38; 
I2 = 0%) (Fig. 5). The risk of dyspepsia (RR 1.08, 95% CI 
0.90–1.30; I2 = 0%) and ulcer-related AEs (RR 2.08, 95% 
CI 0.58–7.46; I2 = 0%) was not significantly increased in the 
COX-2 inhibitor group; however, the risk of abdominal pain 
increased significantly, by 40%, with COX-2 inhibitors (RR 
1.40, 95% CI 1.08–1.80; I2 = 0%).
There was no increase in the relative risk of nausea and 
vomiting (RR 0.96, 95% CI 0.75–1.22; I2 = 0%) nor any sig-
nificant difference in the risk of constipation (RR 1.00, 95% 
CI 0.58–1.75; I2 = 0%) between the COX-2 inhibitors and 
placebo group (ESM2).
3.4.2  Cardiovascular Events
The risk of hypertension increased significantly, by 45% 
overall across the 15 studies, including celecoxib, rofecoxib 
and etoricoxib (RR 1.45, 95% CI 1.01–2.10; I2 = 25%) 
(Fig. 6). However, when rofecoxib was removed from the 
analysis, the risk of hypertension in the COX-2 inhibitor 
group was no longer significant (RR 1.21, 95% CI 0.80–1.83; 
I2 = 20%) (ESM2).
The incidence of heart failure (HF)-related events was 
reported differently across the studies; thus, a grouped analy-
sis was performed. The overall risk of HF and edema was 
increased with COX-2 inhibitors versus placebo (RR 1.68, 
95% CI 1.22–2.31; 0%) (Fig. 7). The overall increase in risk 
of around 70% was not changed appreciably when rofecoxib 
studies were excluded (RR 1.67, 95% CI 1.21–2.29; 0% for 
celecoxib and etoricoxib only) (ESM2).
Fig. 2  Flowchart of the study selection process
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The risk of congestive HF (CHF) was not significantly 
increased (RR 1.18, 95% CI 0.24–5.71; p = 0.944; I2 = 0%). 
The risk of peripheral edema was increased by 61% (RR 
1.61, 95% CI 1.09–2.40; I2 = 0%) and the risk of general-
ized edema increased by 91% (RR 1.91, 95% CI 1.08–3.39; 
I2 = 0%).
3.4.3  Other Primary Outcomes
Central nervous system (CNS) AEs were grouped into diz-
ziness, headache and other (incorporating insomnia, depres-
sion and psychiatric disorders). No appreciable difference 
in the risk of CNS AEs was observed between the placebo 
and COX-2 inhibitor groups (RR 0.94, 95% CI 0.84–1.04; 
0%) (ESM2). Neither was there any increase in the risk of 
dermatological AEs (rash or pruritis) (RR 1.02, 95% CI 
0.76–1.37; 0%) (ESM2). Too few studies reported on renal 
and hepatic AEs and mortality for these to be included in 
the meta-analysis.
The risk of drug-related AEs was significantly increased 
with COX-2 inhibitors versus placebo (RR = 1.26, 95% 
CI 1.09–1.46; I2 = 24%) (Fig. 8). There was no significant 
difference in risk of serious AEs (SAEs) with COX-2 inhib-
itors versus placebo, although a lower rate of SAEs was 
recorded (RR 0.76, 95% CI 0.48–1.19; I2 = 21%) (ESM2).
3.5  Secondary Outcomes
Overall, there was no increase in total risk of AEs between 
the COX-2 inhibitor group and the placebo group, even with 
the highest dose of COX-2 inhibitor included in the analysis 
(RR 1.03, 95% CI 0.97–1.10; I2 = 66%) (ESM2). Too few 
studies reported on withdrawals due to AEs for this to be 
included in the meta-analysis.
3.6  GRADE Assessment of Findings
We assessed the certainty of evidence for each primary or 
secondary outcome for COX-2 inhibitors compared with pla-
cebo, using the GRADE approach [22]. Our findings were 
associated with ‘moderate’ to ‘high’ certainty of evidence. 
Table 2 summarizes the significant findings while Table 3 
summarizes the non-significant findings for the safety out-
comes assessed in this meta-analysis.
Fig. 3  Risk of bias summary: review of authors’ judgements about each risk of bias item for each included study
Fig. 4  Risk of bias graph: review of authors’ judgements about each risk of bias item presented as percentages across all included studies
S36 E. Curtis et al.
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Fig. 5  Relative risk of upper gastrointestinal adverse events (ulcer-related events, dyspepsia, abdominal pain) for COX-2 inhibitors versus pla-
cebo. CI confidence interval, COX-2 cyclooxygenase-2, RR relative risk
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4  Discussion
Overall, our analysis found a significant increased risk of 
drug-related AEs with COX-2 inhibitors compared with pla-
cebo. While it is widely accepted that NSAIDs with COX-2 
selectivity are associated with less gastrointestinal toxicity 
compared with non-selective NSAIDs, nonetheless, our 
study found a 19% increase in upper gastrointestinal AEs 
overall with COX-2 inhibitors compared with placebo, and 
a 40% increase in risk of abdominal pain. This finding is 
in line with another recent meta-analysis from Bhala et al., 
that found an increase in upper gastrointestinal complica-
tions with COX-2 inhibitors, albeit a lower risk than that 
with the non-selective NSAIDs ibuprofen and naproxen, 
but similar to the risk with diclofenac [11]. A retrospective 
pooled analysis of 21 RCTs of 9461 patients aged ≥ 65 years 
with OA, rheumatoid arthritis or ankylosing spondylitis that 
examined the incidence of gastrointestinal AEs (abdominal 
pain, constipation, diarrhea, dyspepsia, flatulence, nausea) 
with celecoxib versus non-selective NSAIDs found a sig-
nificantly lower incidence of gastrointestinal intolerabil-
ity reported with celecoxib than naproxen, ibuprofen or 
diclofenac (p < 0.001) [59].
As may be expected with COX-2 inhibitors, we found a 
significant increase in cardiovascular AEs; specifically, a 
45% increased risk of hypertension that decreased to 21% 
when rofecoxib was excluded from the analysis. Nonselective 
NSAIDs and COX-2 selective inhibitors increase blood pres-
sure in both normotensive subjects as well as in patients 
with hypertension. The mechanism for the increase in blood 
pressure is most likely due to their impact on vasoactive 
endothelium-derived factors, particularly via the inhibition 
of prostaglandin synthesis, important for the regulation of 
vascular tone and sodium excretion [60]. The comparative 
effect of rofecoxib, celecoxib and naproxen on ambulatory 
blood pressure has been studied in 400 patients with arte-
rial hypertension, diabetes mellitus and OA. Rofecoxib, but 
not celecoxib and naproxen, significantly increased 24-hour 
systolic blood pressure after 6 weeks of therapy [61].
Elevated arterial hypertension is a major risk factor for 
stroke, ischemic heart disease and HF [62]. We found a 68% 
overall increase in risk of CHF and edema (peripheral and 
generalized) with COX-2 inhibitors, which was not reduced 
when rofecoxib was excluded from the analysis. A system-
atic review and meta-analysis assessed the risk of developing 
incident HF with the use of NSAIDs for any indication, find-
ing a higher risk of developing HF with NSAIDs, which was 
significantly elevated with non-selective NSAIDs, but not 
with COX-2 inhibitors [63]. The rates of hospital admission 
for CHF with rofecoxib, celecoxib and NSAIDs have been 
compared in 150,000 individuals aged ≥ 65 years. Users of 
rofecoxib and NSAIDs, but not celecoxib, were associated 
with a higher incidence of admission than non-NSAIDs 
users [64].
NOTE: Weights are from random effects analysis






































































































Fig. 6  Relative risk of hypertension adverse events for COX-2 inhibitors versus placebo. CI confidence interval, COX-2 cyclooxygenase-2, RR 
relative risk
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In the Prospective Randomized Evaluation of Celecoxib 
Integrated Safety vs Ibuprofen Or Naproxen (PRECISION) 
trial, celecoxib was found to be non-inferior to naproxen or 
ibuprofen for the primary composite outcome of cardiovas-
cular death (including hemorrhagic death), nonfatal myocar-
dial infarction or nonfatal stroke [65]. In a subgroup analy-
sis of OA patients, fewer major cardiovascular AEs were 
observed in patients treated with celecoxib compared with 
ibuprofen [66]. This confirms the findings of a Japanese pro-
spective observational study of 10,529 patients with OA or 
RA prescribed celecoxib or an NSAID, in which celecoxib 
was not shown to be associated with increased cardiovascu-
lar risk in comparison with NSAIDs [67].
We found no significant increase in the risk of total AEs 
or serious AEs with the use of COX-2 inhibitors (Table 3). 
Neither was there an increase in the rate of constipation, 
nausea and vomiting, CNS AEs or dermatological AEs with 
COX-2 inhibitors versus placebo. Insufficient data on renal 
and hepatic events or death, or withdrawals due to AEs were 
reported to include in this meta-analysis.
4.1  Limitations
Around half of the studies identified from the literature 
search that met the inclusion criteria did not provide AE data 
suitable for inclusion in the meta-analysis. Included studies 
were of short duration, that is, 75% of studies were between 
2 and 26 weeks’ duration. Many studies lacked detail on 
how AEs were collected, with many relying on patient self-
reporting. The grouping of AEs could have led to lack of 
resolution, and possible double counting. In combining dif-
ferent drugs and doses into one meta-analysis, we chose the 
highest dose when multiple doses were presented in a trial, 
which could have led to an exaggeration of AEs. Sensitivity 
analysis of the two approaches (highest dose vs multiple 
dose) revealed only marginal differences in the magnitude 






















































































































































































































Fig. 7  Relative risk of edema (peripheral and generalized) and heart failure adverse events for COX-2 inhibitors versus placebo. CI confidence 
interval, COX-2 cyclooxygenase-2, RR relative risk
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NOTE: Weights are from random effects analysis
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Fig. 8  Relative risk of drug-related adverse events for COX-2 inhibitors versus placebo. AE adverse event, CI confidence interval, COX-2 
cyclooxygenase-2, RR relative risk
Table 2  Summary of significant safety findings for COX-2 inhibitors versus placebo in patients with osteoarthritis
GRADE Working Group grades of evidence: High certainty we are very confident that the true effect lies close to that of the estimate of the 
effect; Moderate certainty we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different; Low certainty our confidence in the effect estimate is limited: the true effect may be substan-
tially different from the estimate of the effect; Very low certainty we have very little confidence in the effect estimate: the true effect is likely to 
be substantially different from the estimate of effect
The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the interven-
tion (and its 95% CI)
CI confidence interval, COX-2 cyclooxygenase-2








Relative effect (95% CI) 
Risk ratio
Anticipated absolute effects






1.26 (1.09–1.46) 144 per 1000 37 more per 1000 (13 more to 
66 more)




1.19 (1.03–1.38) 29 per 1000 5 more per 1000 (1 more to 11 
more)
Abdominal pain 9907 ⊕⊕⊕⊕
HIGH




1.45 (1.01–2.10) 27 per 1000 12 more per 1000 (0 fewer to 30 
more)
Heart failure and edema 14,111 ⊕⊕⊕⊕
HIGH
1.68 (1.22–2.31) 10 per 1000 7 more per 1000 (2 more to 14 
more)
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of the outcome. Our analysis was limited to studies in OA 
patients only; thus, safety issues could be missed in relevant 
subgroups such as in patients after coronary artery bypass 
graft surgery, or in patients with rheumatoid arthritis.
5  Conclusions
Along with non-selective NSAIDs, the use of COX-2 inhibi-
tors in OA is associated with a significant increased risk 
of drug-related AEs compared with placebo. Specifically, 
we found an increased risk of upper-gastrointestinal AEs 
with COX-2 inhibitors, especially abdominal pain. We also 
found an increased risk of cardiovascular AEs with COX-2 
inhibitors, namely hypertension, heart failure and edema. 
Our results confirm that a cautious approach to the use of 
NSAIDs and COX-2 inhibitors for the management of pain 
and inflammation in OA is advisable, with selection of treat-
ment tailored to the individual patient characteristics. In OA 
patients at increased risk of gastrointestinal AEs, COX-2 
inhibitors with the addition of a proton pump inhibitor may 
be used in preference to a non-selective NSAID; while for 
patients at increased risk of cardiovascular AEs, the use of 
COX-2 inhibitors should be avoided. Low-dose celecoxib 
(200 mg/day) may be the preferred NSAID due to its lower 
propensity for gastrointestinal and cardiovascular toxicity. 
To maximize the risk : benefit of NSAIDs, including COX-2 
inhibitors, the European Society for Clinical and Economic 
Aspects of Osteoporosis, Osteoarthritis, and Musculoskel-
etal Diseases (ESCEO) recommends intermittent or longer 
cycles of NSAID use rather than chronic treatment in order 
to minimize safety concerns [68].
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Table 3  Summary of non-significant safety findings for COX-2 inhibitors versus placebo in patients with osteoarthritis
GRADE Working Group grades of evidence: High certainty we are very confident that the true effect lies close to that of the estimate of the 
effect; Moderate certainty we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different; Low certainty our confidence in the effect estimate is limited: the true effect may be substan-
tially different from the estimate of the effect; Very low certainty we have very little confidence in the effect estimate: the true effect is likely to 
be substantially different from the estimate of effect
The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the interven-
tion (and its 95% CI)
CI confidence interval, COX-2 cyclooxygenase-2
a Renal and hepatic events and death were not reported as outcomes in sufficient studies to analyze
b I2 between 50 and 75% (p < 0.001)








Relative effect (95% CI) 
Risk Ratio
Anticipated absolute effects
Risk with placebo Risk difference with COX-2 
inhibitors
Total adverse events 14,908 ⊕⊕⊕◯
MODERATEb
1.03 (0.97–1.10) 471 per 1000 14 more per 1000 (14 fewer to 
47 more)
Serious adverse events 10,393 ⊕⊕⊕⊕
HIGH




1.00 (0.58–1.75) 16 per 1000 0 fewer per 1000 (7 fewer to 12 
more)
Nausea or vomiting 9956 ⊕⊕⊕⊕
HIGH
0.96 (0.75–1.22) 31 per 1000 1 fewer per 1000 (8 fewer to 7 
more)




1.21 (0.80–1.83) 28 per 1000 6 more per 1000 (6 fewer to 23 
more)




0.94 (0.84–1.04) 87 per 1000 5 fewer per 1000 (14 fewer to 
3 more)
Rash or pruritus 4248 ⊕⊕⊕⊕
HIGH
1.02 (0.76–1.37) 36 per 1000 1 more per 1000 (9 fewer to 13 
more)
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